Taiho Pharmaceutical to expand ADC portfolio with Araris Biotech acquisition
Taiho Pharmaceutical is acquiring Araris Biotech for $1.14 billion, strengthening its ADC oncology pipeline. Discover how this deal is shaping the future of cancer treatment. Read More
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a significant milestone in the clinical development of ... Read More